Our study demonstrates an APOE4 allele-dependent decrease in IAPPO-IgA levels and that IAPP-Igs are associated with AD pathology biomarkers and cognitive decline, specifically in APOE4 non-carriers. The gene discussed is CD79A; the disease is Alzheimer disease.